Review
Immunology
Yi-Fan Zeng, Xin-Yu Wei, Qi-Hao Guo, Si-Yu Chen, Sheng Deng, Zheng-Zheng Liu, Zhi-Cheng Gong, Wen-Jing Zeng
Summary: This meta-analysis aimed to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in glioma patients. A total of 20 studies involving 2,321 patients were included. The results showed that PD-1/PD-L1 inhibitors did not significantly improve overall survival (OS) and progression-free survival (PFS), but had a certain efficacy in terms of 6-month, 1-year, and 2-year OS. Furthermore, PD-1/PD-L1 inhibitors were associated with a relatively high incidence of adverse events (70%).
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Shubin Chen, Wanying Mo, Wei Jiang, Shaozhang Zhou, Haijie Gan, Qitao Yu
Summary: This meta-analysis found that PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small cell lung cancer have promising efficacy and safety.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, Research & Experimental
Yumei Gao, Simeng Hu, Ruoyan Li, Shanzhao Jin, Fengjie Liu, Xiangjun Liu, Yingyi Li, Yicen Yan, Weiping Liu, Jifang Gong, Shuxia Yang, Ping Tu, Lin Shen, Fan Bai, Yang Wang
Summary: This study demonstrated that PD-1 acts as a tumor suppressor for malignant T cells with oncogenic TCR activation, based on the analysis of a patient with advanced cutaneous T cell lymphoma who experienced hyperprogression upon anti-PD-1 treatment. PD-1 blockade led to the activation and proliferation of CD4+ malignant T cells, which exhibited functional PD-1 expression and an exhausted status. Somatic amplification of PRKCQ in the malignant T cells resulted in an oncogenic activation of the TCR signaling pathway.
Article
Reproductive Biology
Jue Zhu, Lifeng Yan, Qiming Wang
Summary: The meta-analysis revealed that single PD-1/PD-L1 inhibitors have limited efficacy in ovarian cancer, while the combination with chemotherapy demonstrated a higher response rate. Therefore, the combination of PD-1/PD-L1 inhibitors and chemotherapy should be considered for further research as the recommended approach.
JOURNAL OF OVARIAN RESEARCH
(2021)
Article
Oncology
Wenwen Zhang, Shuang Tong, Bingyang Hu, Tao Wan, Haowen Tang, Feilong Zhao, Tianyu Jiao, Junfeng Li, Ze Zhang, Jinping Cai, Huiyi Ye, Zhanbo Wang, Shiqing Chen, Yafei Wang, Xuerui Li, Fangzhou Wang, Junning Cao, Lantian Tian, Xiaochen Zhao, Mingyi Chen, Hongguang Wang, Shouwang Cai, Minggen Hu, Yuezong Bai, Shichun Lu
Summary: This study investigates the efficacy and safety of lenvatinib plus anti-PD-1 antibodies in the conversion therapy of unresectable HCC. The results show that this treatment regimen has a good conversion success rate and tumor response rate, and can achieve resectability in some patients. The enrichment of CD8+ T cells in pretreatment samples is identified as a promising biomarker for response to this regimen.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Yang Liu, Chunmeng Wang, Xiang Li, Liang Dong, Qingming Yang, Meixia Chen, Fengxia Shi, Malcolm Brock, Miao Liu, Qian Mei, Jiejie Liu, Jing Nie, Weidong Han
Summary: The combination of camrelizumab and decitabine leads to longer progression-free survival in patients with relapsed/refractory cHL compared to camrelizumab monotherapy, showing superior efficacy and potential as a biomarker for treatment response in certain patient subgroups.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Immunology
Andrea Botticelli, Alessio Cirillo, Lidia Strigari, Filippo Valentini, Bruna Cerbelli, Simone Scagnoli, Edoardo Cerbelli, Ilaria Grazia Zizzari, Carlo Della Rocca, Giulia D'Amati, Antonella Polimeni, Marianna Nuti, Marco Carlo Merlano, Silvia Mezi, Paolo Marchetti
Summary: This study compared the efficacy of anti-PD-1 and anti-PD-L1-based therapy in R/M HNSCC patients through a systematic review and network meta-analysis. It found no significant differences in overall survival between different subgroups, except for metastatic patients where anti-PD-1-based therapy was associated with significantly less risk of death.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Jani Huuhtanen, Henna Kasanen, Katriina Peltola, Tapio Lonnberg, Virpi Glumoff, Oscar Bruck, Olli Dufva, Karita Peltonen, Johanna Vikkula, Emmi Jokinen, Mette Ilander, Moon Hee Lee, Siru Makela, Marta Nyakas, Bin Li, Micaela Hernberg, Petri Bono, Harri Lahdesmaki, Anna Kreutzman, Satu Mustjoki
Summary: Relatlimab plus nivolumab (anti-LAG-3+anti-PD-1) has been approved by the FDA for first-line therapy in stage III/IV melanoma, but its impact on the immune system is not well understood. This study evaluated blood samples from 40 metastatic melanoma patients treated with anti-LAG-3+anti-PD-1 and found significant changes in NK cells, Tregs, and CD8+ T cells during the treatment. The study also observed differences in the transcriptome profile and TCR clonality between responders and non-responders.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Review
Pharmacology & Pharmacy
Ze Xiang, Jiayuan Li, Zhengyu Zhang, Chao Cen, Wei Chen, Bin Jiang, Yiling Meng, Ying Wang, Bjoern Berglund, Guanghua Zhai, Jian Wu
Summary: Immunotherapy with immune checkpoint inhibitor (ICI) drugs is a hot topic in cancer treatment. Our study used Bayesian model to comprehensively evaluate the safety and efficacy of ICI drugs. Different ICI drug therapies may have different risks in terms of progression-free survival (PFS), overall survival (OS) and severe adverse events (AEs). Treatment with cemiplimab was found to be the best choice in terms of PFS and OS. Our study provides new insights and strategies for the clinical practice of ICI drugs.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Benjamin C. Creelan, Chao Wang, Jamie K. Teer, Eric M. Toloza, Jiqiang Yao, Sungjune Kim, Ana M. Landin, John E. Mullinax, James J. Saller, Andreas N. Saltos, David R. Noyes, Leighann B. Montoya, Wesley Curry, Shari A. Pilon-Thomas, Alberto A. Chiappori, Tawee Tanvetyanon, Frederic J. Kaye, Zachary J. Thompson, Sean J. Yoder, Bin Fang, John M. Koomen, Amod A. Sarnaik, Dung-Tsa Chen, Jose R. Conejo-Garcia, Eric B. Haura, Scott J. Antonia
Summary: Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) in combination with nivolumab showed potential safety and clinical activity in patients with advanced non-small cell lung cancer, indicating a promising new treatment strategy for metastatic lung cancer.
Article
Oncology
Di Huang, Pengfei Cui, Ziwei Huang, Zhaozhen Wu, Haitao Tao, Sujie Zhang, Rong Xiang, Yi Hu
Summary: This retrospective study evaluated the efficacy and safety of anti-PD-1/L1 plus anti-angiogenesis therapy in patients with advanced lung adenocarcinoma. Results showed that compared to anti-PD-1/L1 monotherapy, the combination therapy significantly improved disease control rate, progression-free survival and overall survival in patients who had failed first-line or later treatment. Further prospective studies are needed to validate these findings.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Medicine, General & Internal
Tanya Siddiqi, David G. Maloney, Saad S. Kenderian, Danielle M. Brander, Kathleen Dorritie, Jacob Soumerai, Peter A. Riedell, Nirav N. Shah, Rajneesh Nath, Bita Fakhri, Deborah M. Stephens, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Serena K. Perna, Sherilyn A. Tuazon, San -San Ou, Eniko Papp, Leanne Peiser, Yizhe Chen, William G. Wierda
Summary: In this study, lisocabtagene maraleucel (liso-cel) was evaluated for its efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The results showed that liso-cel induced complete response or remission in patients, including those who had previously failed treatment with a BTK inhibitor and venetoclax. The safety profile was manageable.
Article
Oncology
Julie Delyon, Lucie Biard, Marion Renaud, Matthieu Resche-Rigon, Jerome Le Goff, Stephane Dalle, Valentine Heidelberger, Laetitia Da Meda, Laurie Toullec, Guislaine Carcelain, Samia Mourah, Sophie Caillat-Zucman, Vincent Allain, Maxime Battistella, Celeste Lebbe
Summary: PD-1 blockade with pembrolizumab shows promising anti-tumor activity and acceptable safety profile in patients with classic and endemic Kaposi sarcoma.
Review
Oncology
Jihane Boustani, Benoit Lecoester, Jeremy Baude, Charlene Latour, Olivier Adotevi, Celine Mirjolet, Gilles Truc
Summary: Combining radiation therapy with immune checkpoint inhibitors shows synergistic potential in enhancing anti-tumor immune responses, although optimization of treatment requires consideration of factors such as dose, fractionation, target volume, lymph nodes, and other immunomodulatory agents.
Article
Oncology
Eva Gine, Fatima de la Cruz, Ana Jimenez Ubieto, Javier Lopez Jimenez, Alejandro Martin Garcia-Sancho, M. Jose Terol, Eva Gonzalez Barca, Maria Casanova, Adolfo de la Fuente, Ana Marin-Niebla, Ana Muntanola, Tomas Jose Gonzalez-Lopez, Marta Aymerich, Xavier Setoain, Montserrat Cortes-Romera, Amanda Rotger, Sonia Rodriguez, Alejandro Medina Herrera, Ramon Garcia Sanz, Ferran Nadeu, Silvia Bea, Elias Campo, Armando Lopez-Guillermo
Summary: The study investigated the effectiveness of tailored treatment with ibrutinib in combination with rituximab (IR) in MCL patients, indicating significant responses in indolent clinical forms of MCL. The frontline IR combination achieved a high rate of complete responses and undetectable minimal residual disease in these patients.
JOURNAL OF CLINICAL ONCOLOGY
(2022)